BMS Streamlining To Focus On Consumer Medicines, Nutritionals

Bristol-Myers Squibb's decision to divest its Clairol cosmetics and Zimmer orthopedic implants businesses in the next 6 to 12 months is part of the company's strategy to focus its resources on its core medicines segments.